Previous 10 | Next 10 |
Boston Scientific press release ( NYSE: BSX ): Q3 Non-GAAP EPS of $0.43 misses by $0.01 . Revenue of $3.17B (+8.2% Y/Y) beats by $30M . MedSurg: 6.5 percent reported, 11.0 percent operational and 9.8 percent organic Cardiovascular: 9.1 percent reported, 15....
Boston Scientific Announces Results for Third Quarter 2022 PR Newswire MARLBOROUGH, Mass. , Oct. 26, 2022 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.170 billion during the third quarter of 2022, growing 8.1 per...
Boston Scientific ( NYSE: BSX ) is scheduled to announce Q3 earnings results on Wednesday, October 26th, before market open. The consensus EPS Estimate is $0.44 (+7.3% Y/Y) and the consensus Revenue Estimate is $3.14B (+7.2% Y/Y). Over the last 2 years, BSX has beate...
Summary The Health Care sector's 2022 return is half as poor as the S&P 500's this year, but the medical device industry features massive losses. One of the best-performing stocks in the industry YTD has an earnings report Wednesday morning. Boston Scientific features a fa...
Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...
Summary Forex, inflation, and component supplies continue to impact the business, but a strong oncology franchise and ongoing MedTech procedure recoveries should drive a satisfactory third quarter. Johnson & Johnson has reported strong clinical and financial results in the dru...
The following slide deck was published by Boston Scientific Corporation in conjunction with this event. For further details see: Boston Scientific (BSX) Presents At Annual Scientific Meeting 2022 of HFSA - Slideshow
Boston Scientific Announces Conference Call Discussing Third Quarter 2022 Results PR Newswire MARLBOROUGH, Mass. , Oct. 3, 2022 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and bus...
Boston Scientific ( NYSE: BSX ) has entered into a collaboration with Truveta , which provides de-identified health data on more than 65M patients, to analyze patient outcomes related to the use of the device company's products. The first analysis under the partnership...
Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...
News, Short Squeeze, Breakout and More Instantly...
Boston Scientific Corporation Company Name:
BSX Stock Symbol:
NYSE Market:
Boston Scientific Corporation Website:
Alkermes plc (ALKS) is expected to report $0.64 for Q2 2024 Acerinox ADR (ANIOY) is expected to report for Q2 2024 Allegion plc (ALLE) is expected to report $1.77 for Q2 2024 Deutsche Bank AG (DB) is expected to report $0.43 for Q2 2024 Pathward Financial Inc. (CASH) is expected t...
Boston Scientific Announces Results for Second Quarter 2024 PR Newswire MARLBOROUGH, Mass. , July 24, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $4.120 billion during the second quarter of 2024, growing 14.5 percent ...
Shares of Boston Scientific Corporation (NYSE: BSX) traded at a new 52-week high today and are currently trading at $78.31. So far today, approximately 1.5M shares have been exchanged, as compared to an average 30-day volume of 5.37M shares. Boston Scientific Corporation develops, manufacture...